Manila Times Business
Phase IIb Study Results of InnoCare’s Orelabrutinib in Patients with SLE Presented at 2026 EULAR
BEIJING, June 05, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that study results of its novel BTK inhibitor orelabrutinib in Phase IIb Study for systemic lupus erythematosus (SLE) were presented at the EULAR 2026 European Congress of Rheumatology in London. The Phase IIb clinical study of orelabrutinib for SLE met its primary and secondary endpoints, making or
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
From Mythical Prophecy to Realism: The Rational Turn of Hu Jiaqi's Doomsday Philosophy
Just now
Energy Awaits When Summer Comes to Play at Galaxy Macau
Just now
Trip.com Kicks Off Winter Travel Season with EOFY Mega Sale and Massive Flight Perks
Just now
Kennedy Center moves to erase Trump references after judge said they were illegally added
Just now